Diagnosis and treatment of cancer using genomics

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Vockley, Joseph G ^a,b   Niederhuber, John E ^a,c  

^a Section of Critical Care Medicine Department of Medicine Inova Fairfax Medical Center   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AZATHIOPRINE; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FIRTECAN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TAMOXIFEN; TEGAFUR; TIOGUANINE; UNINDEXED DRUG; TUMOR MARKER;

ANALYTIC METHOD; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENESIS; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DNA SEQUENCE; GENE IDENTIFICATION; GENE SEQUENCE; GENE TECHNOLOGY; GENOMICS; GERM LINE; HUMAN; HUMAN GENOME; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; ONCOLOGIST; PRIORITY JOURNAL; GENETICS; NEOPLASMS;

CARCINOGENESIS; GENOME, HUMAN; GENOMICS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84936792325     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h1832     Document Type: Article

References (64)

1. Van Dijk EL, Auger H, Jaszczyszyn Y, et al. Ten years of next-generation sequencing technology. Trends Genet 2014;30:418-26.
2. Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014;311:1035-45.
3. Illumina. www.illumina.com/?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=2014&atitle=Illumina&.
4. Life Technologies. Sequencing technology solutions. www.lifetechnologies.com/us/en/home/life-science/sequencing/sequencing-technology-solutions.html?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=2014&atitle=Life%20Technologies&.
5. Roche Diagnostics Corporation. 454 sequencing. www.454.com/?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&atitle=454%20Sequencing&.
6. Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol 1975;94:441-8.
7. Cancer Genome Atlas Research Network; Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013;45:1113-20.
8. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002;62: 4963-7.
9. Gal AA, Cagle PT. The 100-year anniversary of the description of the frozen section procedure. JAMA 2005;294:3135-7.
10. Hall MJ, Forman AD, Pilarski R, et al. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 2014;12:1339-46.
11. National Cancer Institute. Tumor markers. 2011. www.cancer.gov/cancertopics/factsheet/detection/tumor-markers?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=2011&atitle=National%20Cancer%20Institute%3A%20Tumor%20Markers&.
12. US Food and Drugs Administration. Personalized medicine and companion diagnostics go hand-in-hand. 2014. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm407328.htm?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=2014&atitle=Personalized%20Medicine%20and%20Companion%20Diagnostics%20Go%20Hand-in-Hand&.
13. National Cancer Institute. Tumor markers. www.cancer.gov/cancertopics/factsheet/detection/tumor-markers.
14. Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014;11:145-56.
15. Song CX, He C. Balance of DNA methylation and demethylation in cancer development. Genome Biol 2012;13:173.
16. Saumet A, Mathelier A, Lecellier CH. The potential of microRNAs in personalized medicine against cancers. Biomed Res Int 2014;642916, doi:10.1155/2014/642916.
17. Duggan C, Risques R, Alfano C, et al. Change in peripheral blood leukocyte telomere length and mortality in breast cancer survivors. J Natl Cancer Inst 2014;106:dju035.
18. Wu X, Zheng YL, Hsu TC. Mutagen sensitivity as measured by induced chromatid breakage as a marker of cancer risk. Methods Mol Biol 2014;1105:183-92.
19. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez I'homme. C R Acad Sci Paris 1948;142:241-3.
20. Zhong X, Holzgreve W. Circulating cell-free DNA in women's medicine. Global Library of Women's Medicine, 2009, doi:10.3843/GLOWM.10270.
21. Wellcome Trust Sanger Institute. Cancer gene census. 2013. www.sanger.ac.uk/research/projects/cancergenome/census.html?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=2013&atitle=Wellcome%20Trust%20Sanger%20Institute%20Cancer%20Gene%20Census&.
22. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.0
23. National Cancer Institute. Genetic testing for hereditary cancer syndromes. www.cancer.gov/cancertopics/factsheet/Risk/genetic-testing.
24. US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
25. US Food and Drug Administration. FDA allows marketing of four "next generation" gene sequencing devices. 2013. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm375742.htm?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=2013&atitle=FDA%20allows%20marketing%20of%20four%20 %E2%80%9Cnext%20generation%E2%80%9D%20gene%20sequencing%20devices&.
26. Illimina. MiSeqDx Instrument. http://clinical.illumina.com/clinical/diagnostics/ivd-assay-development/miseqdx-instrument.ilmn.
27. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-5.
28. Zhang Z. Genomic landscape of liver cancer. Nat Genet 2012;44:1075-7.
29. Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 2011;305:1568-76.
30. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010;11:685-96.
31. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
32. Lonnstedt IM, Caramia F, Li J, et al. Deciphering clonality in aneuploid tumors using SNP array and sequencing data. Genome Biol 2014;15:470.
33. Penet MF, Krishnamachary B, Chen Z, et al. Molecular imaging of the tumor microenvironment for precision medicine and theranostics. Adv Cancer Res 2014;124:235-56.
34. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274:998-1001.
35. Espina V, Heiby M, Pierobon M, et al. Laser capture microdissection technology. Expert Rev Mol Diagn 2007;7:647-57.
36. Rook MS, Delach SM, Deyneko G, et al. Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping. Am J Pathol 2004;164:23-33.
37. Fang WB, Yao M, Cheng N. Priming cancer cells for drug resistance: role of the fibroblast niche. Front Biol (Beijing) 2014;9:114-26.
38. Akkari L, Gocheva V, Kester JC, et al. Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev 2014;28:2134-50.
39. Ashfaq R. Molecular profiling for personalized cancer care. Clin Exp Metastasis 2012;29:653-5.
40. Olsen D, Jorgensen JT. Companion diagnostics for targeted cancer drugs-clinical and regulatory aspects. Front Oncol 2014;4:105.
41. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
42. Leao M, Pereira C, Bisio A, et al. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. Biochem Pharmacol 2013;85:1234-45.
43. Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem 2014;85:281-319.
44. Grenade C, Phelps MA, Villalona-Calero MA. Race and ethnicity in cancer therapy: what have we learned? Clin Pharmacol Ther 2014;95:403-12.
45. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014;371:497-506.
46. US Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health, Center for Biologics Evaluation and Research. Anticipated details of the draft 2 guidance for industry, food and drug 3 administration staff, and clinical 4 laboratories 5 6 7 framework for regulatory oversight of 8 laboratory developed tests (LDTs). 2013. www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/UCM407409.pdf.
47. European Commission. Revision of the medical device directives. 2014. http://ec.europa.eu/health/medical-devices/documents/revision/index-en.htm?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=2014&atitle=Revision%20of%20the%20Medical%20Device%20Directives&.
48. NCBI. Genetic testing registry. www.ncbi.nlm.nih.gov/gtr/tests/?term=cancer.
49. The benefits of looking across many cancer genomes: a perspective. Cancer Genome Atlas 2013. http://cancergenome.nih.gov/newsevents/newsannouncements/TCGA-Pan-Cancer-Press-Release-2013?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&date=September%2C%2027%202013&atitle=The%20Benefits%20of%20Looking%20Across%20Many%20Cancer%20Genomes%3A%20A%20Perspective&.
50. Sims D, Sudbery I, Ilott NE, et al. Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet 2014;15:121-32.
51. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011;32:177-95.
52. Harismendy O, Schwab RB, Alakus H, et al. Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast Cancer Res 2013;15:R115.
53. Yost SE, Alakus H, Matsui H, et al. Mutascope: sensitive detection of somatic mutations from deep amplicon sequencing. Bioinformatics 2013;29:1908-9.
54. Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014;16:56-67.
55. Laduca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2000 patients. Genet Med 2014;16:830-7.
56. ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet Med 2012;14:759-61.
57. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003;19:660-6.
58. McLeod HL. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 2013;339:1563-6.
59. Mizzi C, Peters B, Mitropoulou C, et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics 2014;15:1223-34.
60. Siva N. 1000 genomes project. Nat Biotechnol 2008;26:256-256b.
61. Genome Reference Consortium. Human genome overview. www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&atitle=Human%20Genome%20Overview&.
62. National Center for Biotechnology Information. RefSeq: NCBI reference sequence database. www.ncbi.nlm.nih.gov/refseq/?sid=Refworks%3AInova%20Fairfax%20Hospital&charset=utf-8&--char-set=utf8&genre=article&atitle=RefSeq%3A%20NCBI%20Reference%20Sequence%20Database&.
63. Gannett L. Biogeographical ancestry and race. Stud Hist Philos Biol Biomed Sci 2014;47:173-84.
64. Bodian DL, McCutcheon JN, Kothiyal P, et al. Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. PLoS One 2014;9:e94554.